Your browser doesn't support javascript.
Pharmacotherapeutics and Vaccines for COVID-19
Medsurg Nursing ; 31(3):188-192, 2022.
Article in English | ProQuest Central | ID: covidwho-1904806
ABSTRACT
Remdesivir Remdesivir (Veklury®), formerly GS-5734, is a monophosphate prodrug with broad-spectrum antiviral activity;its active metabolite binds to the viral RNA-dependent RNA polymerase and inhibits viral replication through premature termination of RNA transcription (Spinner et al., 2020). The Randomized Evaluation of COVID-19 Therapy clinical trial (RECOVERY Collaborative Group, 2021) found hospitalized patients with COVID 19 who were mechanically ventilated or required supplemental oxygen had lower 28day mortality using 6 mg dexamethasone once daily for up to 10 days rather than the standard care alone. [...]dexamethasone may not be used as monotherapy in patients with viral infection because it may inhibit the protective function of T cells and block B cells from making antibodies, potentially leading to increased plasma viral load and delayed viral clearance (Theoharides & Conti, 2020). A randomized controlled trial of hospitalized patients with COVID-19 pneumonia found the use of tofacitinib resulted in lower risk of death or respiratory failure through day 28 than placebo group (Guimaräes et al., 2021).
Keywords
Search on Google
Collection: Databases of international organizations Database: ProQuest Central Topics: Vaccines Language: English Journal: Medsurg Nursing Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: ProQuest Central Topics: Vaccines Language: English Journal: Medsurg Nursing Year: 2022 Document Type: Article